Compare · AGMB vs SGEN
AGMB vs SGEN
Side-by-side comparison of AgomAb Therapeutics NV (AGMB) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGMB and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 56.9x AGMB ($410.2M).
- AGMB has hit the wire 9 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 7 for AGMB).
- Company
- AgomAb Therapeutics NV
- Seagen Inc.
- Price
- -
- -
- Market cap
- $410.2M
- $23.34B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2001
- News (4w)
- 9
- 0
- Recent ratings
- 7
- 25
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest AGMB
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
- SEC Form 4 filed by AgomAb Therapeutics NV
- Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
- SEC Form 4 filed by AgomAb Therapeutics NV
- SEC Form 4 filed by AgomAb Therapeutics NV
- SEC Form 4 filed by AgomAb Therapeutics NV
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
- SEC Form 4 filed by Director Garcia Marino
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)